Premium
Heteroaryl substituted ansa ‐titanocene anti‐cancer drugs derived from fulvenes and titanium dichloride
Author(s) -
Rehmann FranzJosef K.,
Cuffe Laurence P.,
Mendoza Oscar,
Rai Dilip K.,
Sweeney Nigel,
Strohfeldt Katja,
Gallagher William M.,
Tacke Matthias
Publication year - 2005
Publication title -
applied organometallic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.53
H-Index - 71
eISSN - 1099-0739
pISSN - 0268-2605
DOI - 10.1002/aoc.864
Subject(s) - cyclopentadienyl complex , chemistry , fulvenes , fulvene , titanium , medicinal chemistry , stereochemistry , organic chemistry , catalysis
Starting from 2‐furylfulvene (1a) , 2‐thiophenylfulvene (1b) , and 1‐methyl‐2‐pyrrolylfulvene (1c), [1,2‐di(cyclopentadienyl)‐1,2‐di‐(2‐furyl)ethanediyl] titanium dichloride (2a) , [1,2‐di(cyclopentadienyl)‐1,2‐di‐(2‐thiophenyl)ethanediyl] titanium dichloride (2b) , and [1,2‐di(cyclopentadienyl)‐1,2‐bis‐(1‐methyl‐2‐pyrrolyl)ethanediyl] titanium dichloride (2c) were synthesized. When titanocenes (2a–c) were tested against pig kidney carcinoma cells (LLC‐PK), inhibitory concentrations (50%) of 4.5 × 10 −4 M , 2.9 × 10 −4 M and 2.0 × 10 −4 M respectively were observed. Copyright © 2005 John Wiley & Sons, Ltd.